Medicine & Life Sciences
Primary Myelofibrosis
100%
Myelodysplastic Syndromes
65%
Survival
58%
Acute Myeloid Leukemia
57%
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
39%
Karyotype
37%
Mutation
36%
venetoclax
32%
Essential Thrombocythemia
23%
pomalidomide
19%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
19%
Anemia
19%
Systemic Mastocytosis
17%
Therapeutics
16%
Polycythemia Vera
16%
Blast Crisis
16%
Cytogenetics
15%
Neoplasms
14%
Leukemia
14%
Hematologic Neoplasms
12%
High-Throughput Nucleotide Sequencing
11%
Thrombocytosis
11%
Induction Chemotherapy
11%
Azacitidine
11%
Decitabine
10%
Platelet Count
9%
N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide
9%
Second Primary Neoplasms
9%
Mast-Cell Leukemia
8%
midostaurin
8%
Peripheral Nervous System Diseases
8%
Elderly
8%
Vacuoles
8%
Bone Marrow
8%
sapacitabine
8%
imetelstat
8%
Fedratinib
7%
Thrombocytopenia
7%
Transplants
7%
Splenomegaly
7%
Monosomy Chromosome 7
7%
anagrelide
6%
Cladribine
6%
Protein-Tyrosine Kinases
6%
Acute Promyelocytic Leukemia
6%
Chromosome 5q Deletion Syndrome
6%
ponatinib
6%
Hemoglobins
6%
Leukemia, Myelomonocytic, Chronic
6%
Panobinostat
6%